Japan's Mitsubishi Tanabe files for ALS drug edaravone in U.S.

FDA sign
FDA sign

Osaka-based Mitsubishi Tanabe Pharma has moved to get U.S. FDA approval for edaravone (Radicut) to treat amyotrophic lateral sclerosis (ALS) as it moves to expand its product offerings in the key market through collaboration with partners and new a local unit.

In a release, the company said as many as 30,000 people in the U.S. suffer from the progressive neurological condition known as Lou Gehrig's disease after a famous baseball player, with an estimated 5,600 diagnosed each year.

MT Pharma America was started earlier this year as a marketing arm in the U.S. with a target date for approval in 2017 for approval of the ALS candidate.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

U.S. approval for edaravone (MCI-186) would draw on clinical data from Japan where the drug marketed as Radicut was launched around a year earlier to treat ALS patients and has been used since 2001 to treat acute cerebral infarction.

Phase III results of a study on 137 Japanese patients were presented at the American Academy of Neurology meeting in April and demonstrated less functional motor-control loss, compared to standard of care, meeting its primary endpoint.

"There is an urgent need for new treatment approaches that may affect the course of this devastating disorder," Lucie Bruijin, chief scientist of the ALS Association, said in a statement.

- here's the release

Related Article:
Mitsubishi Tanabe says ALS drug meets PhIII endpoint


Suggested Articles

FDA officials say Novartis took too long to launch a formal probe into allegations of Zolgensma data manipulation.

Should Johnson & Johnson owe billions to fix Oklahoma's opioid crisis? After weeks of trial testimony, a judge will have his say Monday afternoon.

After Endo and Allergan agreed to settle with two Ohio counties on opioid charges this week, the state’s AG has a message: You’re not off the hook.